In line with our findings for RIPK1 and pRIPK3, double immunohistochemistry revealed that pMLKL was mainly expressed by NeuN+ pyramidal cortical neurons in the GM, with 1.98% ± 0.5% of total neurons expressing pMLKL in MS cases compared to 0.06% ± 0.06% in controls (Fig. 4e). The gene discussed is RIPK1; the disease is myeloid sarcoma.